China continues to strengthen regulation of Artificial Intelligence ( AI ) in the Life Sciences sectors
In high- risk scenarios such as assisted diagnosis, drug recommendation, and clinical trial participant screening, regulators, including the NMPA and ...
Read the original at Hogan Lovells ↗
- Topics
- Regulation & PolicyChina & GeopoliticsHealthcare
- Mentions
- China
- Tracked via
- “AI Risks”